A PHASE Ib/II STUDY TO EVALUATE SAFETY AND EFFICACY OF ATEZOLIZUMAB COMBINED WITH RADIO-CHEMOTHERAPY IN A PREOPERATIVE SETTING FOR PATIENTS WITH LOCALIZED RECTAL CANCER (R-IMMUNE)
Latest Information Update: 27 Feb 2024
At a glance
- Drugs Atezolizumab (Primary)
- Indications Adenocarcinoma; Rectal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms R-IMMUNE
- 22 Feb 2024 Planned End Date changed from 1 Jan 2024 to 1 Sep 2024.
- 22 Feb 2024 Status changed from recruiting to active, no longer recruiting.
- 24 Oct 2023 Results (n=39) assessing safety and efficacy of atezolizumab combined with radio-chemotherapy in a preoperative setting for patients with locally advanced rectal cancer presented at the 48th European Society for Medical Oncology Congress